Sarcopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Epidemiology, Medication, NDA Approvals, Pipeline, Therapeutics and Companies by DelveInsight

Sarcopenia companies are MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.
(Albany, USA) DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Sarcopenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sarcopenia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Sarcopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sarcopenia market.

Request for a Free Sample Report @ [https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the Key facts of Sarcopenia Market are:

* According to DelveInsight's analysis, sarcopenia market size in the 7MM is expected to grow at a significant CAGR by 2034.
* The total diagnosed prevalent cases of sarcopenia in the 7MM was 27.4 million cases in 2023 and this number is forecasted to climb at a significant CAGR in the research period (2020-2034).
* The Sarcopenia market size in the 7MM reached approximately USD 2,731 million in 2022. Projections indicate a substantial growth during the forecast period.
* Amongst the EU-5 countries, Italy had the highest number of cases followed by Germany with 3,556,282 and 3,194,532 cases respectively. Spain accounted for least number of sarcopenia cases in 2021.
* Japan accounted for 3,104,585 cases sarcopenia in 2021, which accounted for approximately 9% of the total 7MM prevalent cases of sarcopenia.
* According to DelveInsight, males are affected more as compared to females in case of sarcopenia.
* Leading Sarcopenia companies working in the market are MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.
* Sarcopenia therapies expected to launch are Sarconeos (BIO101), MYMD-1, and others.
* In August 2024, TNF Pharmaceuticals, Inc. announced plans to move forward with its lead program, MYMD-1, into fully funded mid-stage clinical trials. The upcoming studies will further investigate the drug's effectiveness in treating sarcopenia/frailty, following statistically significant positive outcomes from a previous Phase II trial.

Sarcopenia Overview

Sarcopenia is a progressive and generalized skeletal muscle disorder characterized by the loss of muscle mass, strength, and function. It primarily affects older adults, contributing significantly to frailty, disability, and reduced quality of life. Sarcopenia can also be associated with chronic diseases, malnutrition, and a sedentary lifestyle.

The onset of sarcopenia is influenced by a combination of age-related changes in muscle tissue, hormonal shifts, inflammation, and decreased physical activity. Muscle fibers shrink and are lost, leading to decreased muscle mass and strength. Additionally, there is often a reduction in the body's ability to synthesize muscle proteins, further exacerbating muscle loss.

Diagnosis of sarcopenia typically involves assessing muscle mass, strength, and physical performance. Tools like dual-energy X-ray absorptiometry (DEXA) scans, grip strength measurements, and gait speed tests are commonly used.

Managing sarcopenia involves a multifaceted approach, including resistance and aerobic exercise to improve muscle strength and function, nutritional interventions such as increased protein intake, and addressing underlying health conditions. In some cases, pharmacological treatments may be considered.

Early identification and intervention are crucial in mitigating the impacts of sarcopenia, helping to maintain independence and improve the overall quality of life in affected individuals. Ongoing research aims to better understand the mechanisms of sarcopenia and develop more effective treatments.

Learn more about Sarcopenia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Sarcopenia Market

The Sarcopenia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Sarcopenia market trends by analyzing the impact of current Sarcopenia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Sarcopenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sarcopenia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Sarcopenia market in 7MM is expected to witness a major change in the study period 2020-2034.

Sarcopenia Epidemiology

The Sarcopenia epidemiology section provides insights into the historical and current Sarcopenia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Sarcopenia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Sarcopenia Epidemiology @ [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Sarcopenia Drugs Uptake

This section focuses on the uptake rate of the potential Sarcopenia drugs recently launched in the Sarcopenia market or expected to be launched in 2020-2034. The analysis covers the Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Sarcopenia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Sarcopenia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Some of the Sarcopenia companies and therapies:

* Biophytis: Sarconeos (BIO101)
* Rejuvenate Biomed: RJx-01
* Lipocine Inc: LPCN 1148
* And Many Others

Sarcopenia Pipeline Development Activities

The Sarcopenia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Sarcopenia key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Sarcopenia pipeline development activities @ [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Sarcopenia Therapeutics Assessment

Major key companies are working proactively in the Sarcopenia Therapeutics market to develop novel therapies which will drive the Sarcopenia treatment markets in the upcoming years are MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.

Learn more about the emerging Sarcopenia therapies & key companies @ [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Sarcopenia Report Key Insights

1. Sarcopenia Patient Population

2. Sarcopenia Market Size and Trends

3. Key Cross Competition in the Sarcopenia Market

4. Sarcopenia Market Dynamics (Key Drivers and Barriers)

5. Sarcopenia Market Opportunities

6. Sarcopenia Therapeutic Approaches

7. Sarcopenia Pipeline Analysis

8. Sarcopenia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Sarcopenia Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Sarcopenia Competitive Intelligence Analysis

4. Sarcopenia Market Overview at a Glance

5. Sarcopenia Disease Background and Overview

6. Sarcopenia Patient Journey

7. Sarcopenia Epidemiology and Patient Population

8. Sarcopenia Treatment Algorithm, Current Treatment, and Medical Practices

9. Sarcopenia Unmet Needs

10. Key Endpoints of Sarcopenia Treatment

11. Sarcopenia Marketed Products

12. Sarcopenia Emerging Therapies

13. Sarcopenia Seven Major Market Analysis

14. Attribute Analysis

15. Sarcopenia Market Outlook (7 major markets)

16. Sarcopenia Access and Reimbursement Overview

17. KOL Views on the Sarcopenia Market

18. Sarcopenia Market Drivers

19. Sarcopenia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sarcopenia-drugs-market-2034-ema-pdma-fda-approvals-clinical-trials-epidemiology-medication-nda-approvals-pipeline-therapeutics-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.